English 
Español
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Related Articles
-
UDIBI
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody. SHOW MORE
-
UDIBI
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile....
-
-
UDIBI
An international comparative analysis and roadmap to sustainable biosimilar markets. SHOW MORE
-
UDIBI
October 6, 2021 Increased survival in puppies affected by Canine Parvovirus type II using an immunomodulator as a therapeutic...
-
UDIBI
Published: September 20, 2019 Utilization of naproxen by Amycolatopsis sp. Poz 14 and detectionof the enzymes involved in the...
-
UDIBI
Published: march 20, 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear magnetic resonance spectroscopy More...
-
UDIBI
CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with LPS and Dialyzable Leukocyte Extract (Transferon®). SHOW MORE
